Company news

NextCure, Inc. news in 2026

NextCure, Inc.'s news releases, calls and decks from 2026, newest first.

View company

NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results

August 6, 2026

NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy

July 14, 2026

NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers

June 3, 2026

NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026

June 1, 2026

NextCure Provides Business Update and Reports First Quarter 2026 Financial Results

May 7, 2026

NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers

May 4, 2026

NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer

April 7, 2026

NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026

March 31, 2026

NextCure Provides Business Update and Reports Full Year 2025 Financial Results

March 4, 2026

NextCure Provides Business Update

January 23, 2026

Decks in 2026